For many primary care physicians, a similar sigh now accompanies the start of Medicare’s “Bridge” program, which promises discounted access to the GLP‑1 weight loss medications Wegovy, Zepbound, and Foundayo. AdvertisementAs of July 1, eligible Medicare beneficiaries may obtain these medications for a sharply discounted out-of-pocket cost of $50 per month. The result is a system that risks creating barriers at precisely the moment when confidence in broader GLP‑1 coverage is most needed. And the gap between promise and reality with GLP-1s has landed squarely on primary care. Faced with these demands, some private practices may decide that participation in the Bridge program is simply not sustainable.